MX381175B - Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma. - Google Patents

Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma.

Info

Publication number
MX381175B
MX381175B MX2016008729A MX2016008729A MX381175B MX 381175 B MX381175 B MX 381175B MX 2016008729 A MX2016008729 A MX 2016008729A MX 2016008729 A MX2016008729 A MX 2016008729A MX 381175 B MX381175 B MX 381175B
Authority
MX
Mexico
Prior art keywords
clomipramine
pharmaceutical composition
composition containing
pharmaceutical preparation
preparing same
Prior art date
Application number
MX2016008729A
Other languages
English (en)
Other versions
MX2016008729A (es
Inventor
Bong- Sang LEE
Dong- Jin Lee
Hong Ryeol Jeon
Jung- Hwa KIM
Seong-Shin Kwak
Hyun-Jung Park
Original Assignee
Ctc Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ctc Bio Inc filed Critical Ctc Bio Inc
Publication of MX2016008729A publication Critical patent/MX2016008729A/es
Publication of MX381175B publication Critical patent/MX381175B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona una formulación farmacéutica que comprende clomipramina o su sal farmacéuticamente aceptable (preferiblemente, hidrocloruro de clomipramina) como el primer ingrediente activo, y sildenafil o su sal farmacéuticamente aceptable (preferiblemente, citrato de sildenafil) como el segundo ingrediente activo, en donde la estabilidad de la clomipramina es mejorada, y un método para fabricar esta formulación farmacéutica. En particular, la presente invención proporciona una formulación farmacéutica que comprende los dos ingredientes activos anteriores y es fabricada mediante el uso de un método de granulación en húmedo, en donde la estabilidad de la clomipramina es mejorada, y un método para la fabricación de esta formulación farmacéutica.
MX2016008729A 2013-12-31 2014-12-29 Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma. MX381175B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20130168702 2013-12-31
PCT/KR2014/012969 WO2015102337A1 (ko) 2013-12-31 2014-12-29 클로미프라민 함유 약학 조성물 및 이의 제조 방법

Publications (2)

Publication Number Publication Date
MX2016008729A MX2016008729A (es) 2017-02-28
MX381175B true MX381175B (es) 2025-03-12

Family

ID=53493626

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016008729A MX381175B (es) 2013-12-31 2014-12-29 Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma.
MX2021000769A MX394413B (es) 2013-12-31 2014-12-29 Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021000769A MX394413B (es) 2013-12-31 2014-12-29 Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma

Country Status (8)

Country Link
US (2) US10045944B2 (es)
EP (1) EP3090732B1 (es)
KR (3) KR20150079449A (es)
CN (1) CN105899193A (es)
BR (1) BR112016015175A2 (es)
ES (1) ES2988594T3 (es)
MX (2) MX381175B (es)
WO (1) WO2015102337A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX381175B (es) * 2013-12-31 2025-03-12 Ctc Bio Inc Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma.
CN108126203A (zh) * 2018-01-05 2018-06-08 黄平 一种药物组合物及其药物递送系统与用途
US11957692B2 (en) 2022-05-23 2024-04-16 National Institute Of Immunology Clomipramine for the treatment of Alzheimer's Disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
US6495154B1 (en) * 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
US6863901B2 (en) * 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
EP1896076A2 (en) * 2005-06-27 2008-03-12 Daniel Drai Compositions and methods for enhancement of sexual function
EP3263117A1 (en) * 2005-11-28 2018-01-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
CA2722845A1 (en) 2008-05-19 2009-11-26 Yuhan Corporation Pharmaceutical composition for the treatment of premature ejaculation
BR112013033475A2 (pt) 2011-06-28 2017-12-19 Ctc Bio Inc composição farmacêutica para tratamento, prevenção ou melhora da ejaculação precoce e método para tratamento, prevenção ou melhora da ejaculação precoce
MX381175B (es) * 2013-12-31 2025-03-12 Ctc Bio Inc Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma.

Also Published As

Publication number Publication date
US20180311170A1 (en) 2018-11-01
US10045944B2 (en) 2018-08-14
MX394413B (es) 2025-03-24
CN105899193A (zh) 2016-08-24
MX2016008729A (es) 2017-02-28
BR112016015175A2 (pt) 2017-08-08
ES2988594T3 (es) 2024-11-21
EP3090732A4 (en) 2017-06-28
MX2021000769A (es) 2022-07-29
KR20220017458A (ko) 2022-02-11
EP3090732B1 (en) 2024-07-24
EP3090732A1 (en) 2016-11-09
KR20150079449A (ko) 2015-07-08
KR102357423B1 (ko) 2022-02-08
US20160324789A1 (en) 2016-11-10
US10512610B2 (en) 2019-12-24
WO2015102337A1 (ko) 2015-07-09
KR20210104618A (ko) 2021-08-25
KR102527999B1 (ko) 2023-05-02

Similar Documents

Publication Publication Date Title
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
MX363347B (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
JO3430B1 (ar) مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
NI201500135A (es) Composición farmacéutica de hidrocloruro de s-ketamina
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
MY197785A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
BR112015018087A8 (pt) composto, composição farmacêutica e uso
MX2017014994A (es) Formulacion solida oral que contiene irinotecano y metodo de preparacion de la misma.
SG10201804817TA (en) Delayed release compositions of linaclotide
WO2017127835A3 (en) Aqueous formulations and methods of preparation and use thereof
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
MX2017012295A (es) Derivados formilados n-heterociclicos como inhibidores de fgfr4.
BR112015010271A8 (pt) produto de comicronização, processo para o preparo de um produto de comicronização, composição farmacêutica e seus usos
EA201691741A1 (ru) Фармацевтическая композиция
EA201692298A1 (ru) Производные карбоксамидов
MX2016001422A (es) Composicion farmaceutica de fingolimod.
WO2014145314A3 (en) Methods and compositions for gamma-glutamyl cycle modulation
MX381175B (es) Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma.
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
MX385513B (es) Composiciones farmaceuticas que comprenden safinamida.
DK3882244T3 (da) Forbindelse, farmaceutisk acceptabelt salt eller optisk isomer deraf, fremgangsmåde til fremstilling af samme og farmaceutisk sammensætning til forebyggelse eller behandling af virussygdomme indeholdende samme som aktiv ingrediens
CO2020006552A2 (es) Composiciones farmaceuticas que comprenden safinamida
PH12016502527A1 (en) Stabilized desmopressin
EA201491477A1 (ru) Фармацевтические составы, содержащие флупиртин